A phase change probe of LRRK2 kinase and its application

By designing the LRRK2 kinase phase transition probe, the specific interaction between Rab10 and RILPL2 proteins is used to form phase transition droplets, which solves the problems of complicated detection of LRRK2 kinase activity and low screening efficiency in the prior art, and achieves rapid and visual detection and efficient inhibitor screening.

CN118460579BActive Publication Date: 2024-11-26SHANDONG BOGUAN IMAGING BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410930837.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-12
Publication Date
2024-11-26
Estimated Expiration
2044-07-12

AI Technical Summary

Technical Problem

The prior art is complicated to detect LRRK2 kinase activity, time consuming and poor repeatability, difficult to perform high-throughput screening, and low signal-to-noise ratio, making it impossible to achieve rapid visual detection and cost-effective LRRK2 kinase inhibitor screening.

Method used

A phase transition probe of LRRK2 kinase was designed to construct a combination of Rab10 and RILPL2 proteins and fluorescent proteins by encoding specific DNA sequences. The specific interaction between LRRK2 kinase phosphorylated substrate and binding protein was used to form a visual phase transition solution. Drops, achieving rapid detection of LRRK2 kinase activity and inhibitor screening.

Benefits of technology

Rapid visual detection of LRRK2 kinase activity is realized, which improves detection sensitivity and signal-to-noise ratio, simplifies operation, and can perform high-connotation screening and quantitative analysis in living cell systems, significantly improving the efficiency of screening of LRRK2 kinase inhibitors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118460579B_ABST
    Figure CN118460579B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biological imaging technology, and relates to a phase change probe of LRRK2 kinase and its application. The phase change probe of the present invention comprises DNA sequences encoding the following proteins or peptides in sequence: Rab10, fluorescent protein, HOTAg3, RILPL2, fluorescent protein, HOTAg6; wherein, the DNA sequence encoding HOTAg3 is shown in SEQ ID NO.5; wherein, the DNA sequence encoding HOTAg6 is shown in SEQ ID NO.8. The above phase change probe can be applied to the rapid visualization detection of LRRK2 kinase activity and the high-cost-effective and high-content screening of LRRK2 kinase inhibitors. The probe of the present invention can record the results under a fluorescence microscope and can be automatically quantified using high-content software.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biological imaging, and relates to a phase change probe of LRRK2 kinase and an application thereof, and in particular to an application of the phase change probe of LRRK2 kinase in high content screening. Background Art

[0002] Parkinson's disease (PD) is the second most common neurodegenerative disease, with a worldwide prevalence of 1.7% in people over 65 years old. Genetic studies have found that there are more than 100 LRRK2 gene mutations in Parkinson's patients. Carriers of LRRK2 gene mutations account for 4%-10% of familial Parkinson's patients and 1%-2% of sporadic Parkinson's patients. Among them, LRRK2-G2019S mutation carriers alone account for about 1% of the total Parkinson's disease population. In addition, LRRK2 gene mutations are also an important risk factor for Crohn's disease (CD), an immune enteritis. Most pathogenic LRRK2 gene mutations increase the kinase activity of LRRK2. Moreover, in pathological studies of brain slices of deceased patients with sporadic Parkinson's disease, it was found that even if the patient did not carry the LRRK2 gene mutation, the wild-type LRRK2 kinase activity was abnormally increased. Therefore, LRRK2 kinase activity inhibitors are very promising as therapeutic targets for the course of Parkinson's disease.

[0003] At present, many pharmaceutical companies around the world have developed more than 100 inhibitors targeting LRRK2 kinase. Rapid detection of LRRK2 kinase activity and search for LRRK2 kinase inhibitors as drugs for the treatment of Parkinson's disease have broad market prospects. At present, the phosphorylation level of LRRK2 itself and substrates is mainly detected by protein immunoblotting or immunofluorescence methods to indicate LRRK2 kinase activity. This method is cumbersome, time-consuming, dependent on antibody quality, poor reproducibility, low reliability, and difficult to perform high-throughput screening. Summary of the invention

[0004] In view of the deficiencies in the above-mentioned prior art, the present invention provides a phase change probe of LRRK2 kinase and its application. The phase change probe of the present invention has strong specificity, sensitive reaction, extremely high signal-to-noise ratio, and simple operation, and can realize rapid visual detection of LRRK2 kinase activity and cost-effective and high-content screening of LRRK2 kinase inhibitors.

[0005] The specific technical solutions are as follows:

[0006] One of the purposes of the present invention is to provide a phase change probe of LRRK2 kinase, which comprises DNA sequences encoding the following proteins or peptides in sequence: Rab10, fluorescent protein, HOTAg3, RILPL2, fluorescent protein, HOTAg6;

[0007] Wherein, the DNA sequence encoding HOTAg3 is shown as SEQ ID NO.5;

[0008] Among them, the DNA sequence encoding HOTAg6 is shown as SEQ ID NO.8.

[0009] Wherein, Rab10 is a substrate of LRRK2 kinase, and the DNA sequence encoding Rab10 (wild type, Rab10-WT) preferably includes the sequence shown in SEQ ID NO.1.

[0010] Among them, RILPL2 is a specific binding protein after the phosphorylation modification of threonine (Thr) at position 73 of Rab10, and the DNA sequence encoding RILPL2 (wild type, RILPL2-WT) preferably includes the sequence shown in SEQ ID NO.7.

[0011] Wherein, the fluorescent protein is preferably green fluorescent protein eGFP; the DNA sequence encoding eGFP is shown in SEQ ID NO.3.

[0012] The mechanism of the present invention is as follows:

[0013] LRRK2 kinase can phosphorylate a series of Rab GTPase proteins. After the threonine 73 (Thr73) of the representative substrate Rab10 is phosphorylated by LRRK2, the phosphorylated form of Rab10 (Phospho-Thr73-Rab10) specifically binds to the RILPL2 protein; in contrast, the non-phosphorylated form of Rab10 cannot bind to RILPL2 at all.

[0014] According to this characteristic, the present invention designs Rab10 and RILPL2 to connect oligomerized peptides HOTag3 (Homo-Oligomeric Tag 3, a hydrophobic peptide, forming a hexamer in the cell) and HOTag6 (a hydrophobic peptide, forming a tetramer in the cell), respectively, to construct Rab10-eGFP-HOTag3 and RILPL2-eGFP-HOTag6. At the same time, the two are connected with a self-cleaving short peptide T2A to ensure that the molar ratio of the protein expression of the two is 1:1. After the hexameric Rab10-eGFP is phosphorylated by the LRRK2 kinase, it specifically binds to the tetrameric RILPL2-eGFP. The two bind asymmetrically, and the excess monomers will recruit adjacent oligomers to trigger a phase change, eventually forming a phase change droplet with a diameter of about 2 μm. The detection of LRRK2 kinase activity is transformed into the detection of the number of green phase-change droplets or the total fluorescence intensity, which greatly improves the detection sensitivity of LRRK2 kinase activity while facilitating detection, and realizes the visualization of LRRK2 kinase activity in living cell systems. The probe of the present invention can record the results under a fluorescence microscope and can be automatically quantified using high-content software (preferably Thermo Scientific HCS Studio: Cellomics Scan Version 6.6.3). Experiments with various mutant control groups and LRRK2 inhibitor treatment groups have confirmed that the probe of the present invention has specificity.

[0015] In the present invention, after LRRK2 kinase phosphorylates the threonine (Thr73) at position 73 of the substrate Rab10, the key is that the phosphorylated Rab10 can specifically bind to RILPL2. Therefore, the degree of interaction between phosphorylated Rab10 and RILPL2 reflects the activity of LRRK2 kinase, which is further characterized by the number of green droplets formed by the probe or the total fluorescence intensity, thereby realizing the visualization of LRRK2 kinase activity in a living cell system.

[0016] Preferably, a self-cleaving short peptide T2A is also included between HOTAg3 and RILPL2. T2A ensures that the eukaryotic expression plasmid is translated into two complete parts in the cell and ensures that the molar ratio of protein expression is 1:1. The DNA sequence encoding T2A preferably includes the sequence shown in SEQ ID NO.6. SEQ ID NO.6 is a sequence that does not include an enzyme cleavage site, and the DNA sequence encoding T2A including an enzyme cleavage site is preferably as shown in SEQ ID NO.11.

[0017] Preferably, the phase change probe of the present invention further comprises a DNA sequence encoding a linker. Various linkers are within the range of 6-30 flexible amino acids (excluding enzyme cleavage sites) to facilitate the operation of the probe.

[0018] More preferably, the Linker includes Linker1 and Linker2.

[0019] Among them, Linker1 is preferably connected between Rab10 and the first fluorescent protein, and between RILPL2 and the second fluorescent protein, and Linker2 is preferably connected between the first fluorescent protein and HOTAg3, and between the second fluorescent protein and HOTAg6.

[0020] Specifically, the phase change probe includes DNA sequences encoding the following proteins or peptides in sequence: Rab10-Linker1-eGFP-Linker2-HOTag3-T2A-RILPL2-Linker1-eGFP-Linker2-HOTag6.

[0021] The DNA sequence encoding Linker1 includes the sequence shown in SEQ ID NO.2; SEQ ID NO.2 is a sequence excluding the restriction site, and the DNA sequence encoding Linker1 including the restriction site is preferably shown in SEQ ID NO.9.

[0022] Among them, the DNA sequence encoding Linker2 includes the sequence shown in SEQ ID NO.4; SEQ ID NO.4 is a sequence excluding the restriction site, and the DNA sequence encoding Linker2 including the restriction site is preferably as shown in SEQ ID NO.10.

[0023] The second object of the present invention is to provide the use of the above phase change probe in detecting the kinase activity of LRRK2.

[0024] Specifically, the following method can be used to detect the activity of LRRK2 kinase: the phase change probe can be cloned into a eukaryotic expression vector (preferably a pcDNA3.1 plasmid), and co-transfected into cells with a plasmid cloned with the LRRK2 kinase gene, which can then phase change to form green droplets. The total number of green phase change droplets / total number of cells can be used to show the degree of activation of LRRK2 kinase. The total number of cells is indicated by a nuclear localized 3NLS-mCherry probe.

[0025] The third object of the present invention is to provide the use of the above phase change probe in the screening of LRRK2 kinase inhibitors.

[0026] Specifically, the phase change probe can be used to screen LRRK2 kinase inhibitors in the following manner: the phase change probe can be cloned into a eukaryotic expression vector, co-transfected into cells with a plasmid cloned with the LRRK2 kinase gene, and then the inhibitor to be screened is added, followed by imaging and recording of high-brightness droplets expressed in the cells. Existing LRRK2 kinase inhibitors can be used as positive controls: such as Genentech's GNE-7915 (MCE No.: HY-18163), Pfizer's PFE-360 (MCE No.: HY-120085), and Merck's MLi-2 (MCE No.: HY-100411); DMSO is preferably used as a negative control. High-content software can be used to achieve quantitative analysis of the effects of the compounds to be screened on the activity of LRRK2 kinase.

[0027] The beneficial effects of the present invention are as follows:

[0028] The phase change probe of the present invention is the first to detect LRRK2 kinase activity in living cells. The probe of the present invention has strong specificity in living cells, extremely high signal-to-noise ratio, simple operation, and can be used for high-content screening and quantitative analysis. The probe of the present invention can record the results in a high-content imaging platform (such as Thermo Scientific CX7 Pro or M7000) and can be used for automated quantification using high-content software (Thermo Scientific HCS Studio: Cellomics Scan Version 6.6.3).

[0029] The probe of the present invention has high signal recognition, and the phase change forms a phase change droplet with a diameter of about 2 μm. The probe designed by the present invention increases the intensity of fluorescent protein and imaging pixels by more than about 1000 times.

[0030] The phase-change probe of the present invention has high sensitivity. The present invention utilizes the asymmetric combination of hexamers and tetramers to generate phase-change droplets, thereby increasing the detection sensitivity of kinase activity by 2-3 orders of magnitude. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 It is a schematic diagram of the structure and working effect of the phase change probe in a specific implementation manner;

[0032] Figure 2 The imaging results of verifying the specificity of the phase change probe using three LRRK2 inhibitors with different structural types in Example 2;

[0033] Figure 3 The results of the analysis of the phase change probe specificity verified using three LRRK2 inhibitors with different structural types in Example 2;

[0034] Figure 4The imaging results of Example 3 verifying the specificity of the phase change probe from the single-point mutation of important amino acids in the interaction interface between the substrate Rab10 and the RILPL2 protein;

[0035] Figure 5 The results of the analysis of the single-point mutation of important amino acids in the interaction interface between the substrate Rab10 and the RILPL2 protein in Example 3 to verify the specificity of the phase change probe;

[0036] Figure 6 The imaging results of Example 4 verifying the specificity of the phase change probe by mutations that cause loss of LRRK2 kinase activity and demonstrating the imaging results of changes in LRRK2 kinase activity caused by common mutations in Parkinson's disease;

[0037] Figure 7 The results of the analysis in Example 4 verifying the specificity of the phase change probe by mutations that cause loss of LRRK2 kinase activity and demonstrating changes in LRRK2 kinase activity caused by common mutations in Parkinson's disease;

[0038] Figure 8 This is a scatter plot of the screening of LRRK2 inhibitors using phase change probes in Example 5. DETAILED DESCRIPTION

[0039] The principles and features of the present invention are described below in conjunction with examples. The examples are only used to explain the present invention and are not used to limit the scope of the present invention.

[0040] In a specific embodiment, the phase change probe of LRRK2 kinase is composed of the following protein or peptide DNA sequences in order: Rab10-Linker1-eGFP-Linker2-HOTag3-T2A-RILPL2-Linker1-eGFP-Linker2-HOTag6.

[0041] Wherein, the DNA sequence encoding Rab10 is shown as SEQ ID NO.1;

[0042] Wherein, the DNA sequence encoding Linker1 is shown as SEQ ID NO.9;

[0043] Wherein, the DNA sequence encoding eGFP is shown as SEQ ID NO.3;

[0044] Wherein, the DNA sequence encoding Linker2 is preferably as shown in SEQ ID NO.10;

[0045] Wherein, the DNA sequence encoding HOTAg3 is shown as SEQ ID NO.5;

[0046] Wherein, the DNA sequence encoding T2A is shown as SEQ ID NO.11;

[0047] Wherein, the DNA sequence encoding RILPL2 is shown as SEQ ID NO.7;

[0048] Among them, the DNA sequence encoding HOTAg6 is shown as SEQ ID NO.8.

[0049] The core design principle and working effect diagram of the above phase change probe are shown in the figure. Figure 1 shown.

[0050] In a specific embodiment: Rab10-T73A is a mutation of threonine (Thr) at position 73 of Rab10 to alanine (Ala), and the DNA sequence encoding Rab10-T73A is shown in SEQ ID NO.12; RILPL2-R130E is a mutation of arginine (Arg) at position 130 of RILPL2 to glutamic acid (Glu), and the DNA sequence encoding RILPL2-R130E is shown in SEQ ID NO.13; RILPL2-R132E is a mutation of arginine (Arg) at position 132 of RILPL2 to glutamic acid (Glu), and the DNA sequence encoding RILPL2-R132E is shown in SEQ ID NO.14; RILPL2-K149E is a mutation of lysine (Lys) at position 149 of RILPL2 to glutamic acid (Glu), and the DNA sequence encoding RILPL2-K149E is shown in SEQ ID NO.15.

[0051] In a specific embodiment: the DNA sequence encoding LRRK2 (wild type, LRRK2-WT) is shown in SEQ ID NO.16; LRRK2-G2019S is a mutation of glycine (Gly) at position 2019 of LRRK2 to serine (Ser), and the DNA sequence encoding LRRK2-G2019S is shown in SEQ ID NO.17; LRRK2-3×KD is a mutation of lysine (Lys) at position 1906 to serine (Ala), aspartic acid (Asp) at position 1994 to serine (Ala), and aspartic acid (Asp) at position 2017 to serine (Ala) of LRRK2, and the DNA sequence encoding LRRK2-3×KD is shown in SEQ ID NO.18.

[0052] In a specific embodiment: the DNA sequence encoding 3NLS-mCherry is shown as SEQ ID NO.19; wherein the fluorescent protein mCherry DNA sequence is shown as SEQ ID NO.20. Example 1

[0053] Construct a phase-change probe vector. The steps are as follows:

[0054] (1) Construction of phase change probe vector and its corresponding control mutation vector:

[0055] Based on the principle that LRRK2 kinase phosphorylates the substrate Rab10 and RILPL2 can specifically bind to the phosphorylated form of Rab10, the phase change probe vector plasmid of LRRK2 kinase was cloned and constructed, marked as pcDNA3.1-Rab10-eGFP-HOTag3-T2A-RILPL2-eGFP-HOTag6 (the probe sequence also includes Linker).

[0056] Using the probe plasmid as a template, primers were designed to obtain fragments of Rab10 and RILPL2 mutations with restriction sites by PCR amplification: Rab10-T73A, RILPL2-R130E, RILPL2-R132E and RILPL2-K149E; the PCR fragment of Rab10-T73A was digested with NheI and KpnI enzymes to obtain the sticky end fragment of Rab10-T73A; the pcDNA3.1-Rab10-eGFP-HOTag3-T2A-RILPL2-eGFP-HOTag6 plasmid was digested with NheI and KpnI enzymes to obtain pcD NA3.1-(NheI / KpnI)-eGFP-HOTag3-T2A-RILPL2-eGFP-HOTag6 vector; the Rab10-T73A mutant fragment with restriction site was inserted into the pcDNA3.1-(NheI / KpnI)-eGFP-HOTag3-T2A-RILPL2-eGFP-HOTag6 vector by T4 ligation to form pcDNA3.1-Rab10-T73A-eGFP-HOTag3-T2A-RILPL2-eGFP-HOTag6 plasmid; HindIII was used to The pcDNA3.1-Rab10-eGFP-HOTag3-T2A-RILPL2-eGFP-HOTag6 plasmid was digested with EcoRI to obtain the pcDNA3.1-Rab10-eGFP-HOTag3-T2A-(HindIII / EcoRI)-eGFP-HOTag6 vector; the RILPL2-R130E, RILPL2-R132E and RILPL2-K149E mutant fragments with restriction sites were inserted into the pcDNA3.1-Rab10-eGFP-HOTag3-T2A-RILPL2-eGFP-HOTag6 plasmid by T4 ligation. A-(HindIII / EcoRI)-eGFP-HOTag6 vector was used to form pcDNA3.1-Rab10-eGFP-HOTag3-T2A-RILPL2-R130E-eGFP-HOTag6, pcDNA3.1-Rab10-eGFP-HOTag3-T2A-RILPL2-R132E-eGFP-HOTag6 and pcDNA3.1-Rab10-eGFP-HOTag3-T2A-RILPL2-K149E-eGFP-HOTag6 plasmids, and the correctness was verified by sequencing.

[0057] (2) Construction of LRRK2 mutation vector:

[0058] Primers were designed and pCMV-Tag3B-LRRK2 plasmid (purchased from Addgene) was used as a template for PCR amplification to obtain LRRK2 mutant fragments with restriction sites: LRRK2-G2019S and LRRK2-3×KD; the PCR fragments of LRRK2-G2019S and LRRK2-3×KD were digested with SpeI and SalI enzymes to obtain the sticky end fragments of LRRK2-G2019S and LRRK2-3×KD; the pCMV-Tag3B-LRRK2 plasmid was digested with SpeI and SalI enzymes to obtain the pCMV-Tag3B-(SpeI / SalI) vector. The sticky-end fragment of the LRRK2 mutation with restriction sites was inserted into the pCMV-Tag3B-(SpeI / SalI) vector by the T4 ligation method to form pCMV-Tag3B-LRRK2-G2019S and pCMV-Tag3B-LRRK2-3×KD plasmids, which were verified correct by sequencing.

[0059] (3) The pCMV-Tag3B-3NLS-mCherry full-length sequence vector was cloned and constructed, and the correctness was verified by sequencing.

[0060] (4) Transform, amplify and recover the plasmid vector constructed above:

[0061] The plasmid was transformed with the Stbl3 strain and amplified in a bacterial culture medium LB containing kanamycin. The plasmid was purified using an endotoxin-free plasmid extraction kit and dissolved in TE buffer. Example 2

[0062] At present, a variety of specific inhibitors developed based on the rational design of LRRK2 structure have entered the preclinical research stage. In Example 2, three small molecule inhibitors with different structural types (GNE-7915, PFE-360 and MLi-2) were used to verify the specificity of the phase change probe of the present invention. The steps are as follows:

[0063] (1) Plating: HEK 293T cells were plated at 1.3 × 10 cells per well. 4 The cells were evenly plated on a 96-well cell culture plate at a density of 100 μL per well, and cultured in a 37°C, 5% CO2 incubator.

[0064] (2) Cell transfection: After the cells are plated and cultured for 20 hours, cell transfection is performed. The specific steps are as follows:

[0065] a. For each well of cells, use 10 μL Opti-MEM serum-free medium to dilute 250 ng pcDNA3.1-Rab10-eGFP-HOTag3-T2A-RILPL2-eGFP-HOTag6 plasmid, 100 ng pCMV-Tag3B-3NLS-mCherry plasmid and 50 ng pCMV-Tag3B-LRRK2-G2019S plasmid, mix well to make DNA dilution solution, and let stand for 5 minutes; use 10 μL Opti-MEM serum-free medium to dilute 0.6 μL PEI 40000 transfection reagent (YEASEN), mix well to make PEI 40000 dilution solution, and let stand for 5 minutes.

[0066] b. Mix the DNA dilution and PEI 40000 dilution and incubate at room temperature for 20 minutes to form a DNA-PEI cationic nucleic acid transfection reagent complex.

[0067] c. After the complex formation process, remove 20 μL of cell growth medium and add 20 μL of DNA-PEI cationic nucleic acid transfection reagent complex to each well; shake the culture plate and mix gently.

[0068] d. The cells were cultured in a 37°C, 5% CO2 incubator. One hour after transfection, 75 μL of the original cell growth medium in the wells was removed and 175 μL of fresh pre-warmed DMEM high-glucose medium containing 10% FBS was added to each well to maintain the medium volume of each well at 200 μL.

[0069] (3) Drug addition: After changing the medium, three LRRK2 inhibitors were added to the positive cells transfected with pCMV-Tag3B-LRRK2-G2019S, pcDNA3.1-Rab10-eGFP-HOTag3-T2A-RILPL2-eGFP-HOTag6 and pCMV-Tag3B-3NLS-mCherry plasmids: GNE-7915, PFE-360 and MLi-2 as positive control drugs; DMSO (dimethyl sulfoxide) was added as a negative control. The final drug concentration in each well was 5 μM, and three replicates were added for each group.

[0070] (4) Photography: 24 hours after transfection, 12 fields of view were randomly selected from each well using the CX7Pro high-content rapid imaging platform (Thermo Fisher) with a 20x high-definition lens. The experimental imaging results are shown in Figure 2. Figure 2 shown.

[0071] (5) Quantitative method: The position of the cell nucleus is determined by the independently expressed pCMV-Tag3B-3NLS-mCherry in the probe, thereby determining the number of transfected cells; the total number of green phase change droplets in the field of view / total number of cells, that is, the average number of green droplets in each cell, is used to show the degree of LRRK2 kinase activation. The result data of the negative control group with DMSO added is taken as 1, and the graph is normalized and analyzed. Figure 3 As shown. After transfection, the probe phase changes to form green droplets. The number of green fluorescent droplets in the three inhibitor groups of GNE-7915, PFE-360 and MLi-2 is less than that in the DMSO group, indicating that the three inhibitors of GNE-7915, PFE-360 and MLi-2 have an inhibitory effect on the kinase activity of LRRK2, demonstrating the specificity of the phase change probe of the present invention. Example 3

[0072] The specificity of the phase change probe of the present invention was verified by ① mutation of the threonine (Thr) phosphorylation site at position 73 of the LRRK2 kinase substrate Rab10 and ② mutation of the key amino acid residues (130, 132, 149) for the specific binding of RILPL2 to the phosphorylated form of Rab10 (pThr73-Rab10). The steps are as follows:

[0073] (1) Plating: HEK 293T cells were plated at 1.3 × 10 cells per well. 4 The cells were evenly plated on a 96-well cell culture plate at a density of 100 μL per well, and cultured in a 37°C, 5% CO2 incubator.

[0074] (2) Cell transfection: After the cells are plated and cultured for 20 hours, cell transfection is performed. The specific steps are as follows:

[0075] a. For each well of cells, dilute 100 ng of pCMV-Tag3B-3NLS-mCherry plasmid, 100 ng of pCMV-Tag3B-LRRK2-G2019S, and 250 ng of pcDNA3.1-Rab10-eGFP-HOTag3-T2A-RILPL2-eGFP-HOTag6 or pcDNA3.1-Rab10-T73A-eGFP-HOTag3-T2A-RILPL2-eGFP-HOTag6 or pcDNA3.1-Rab10-eGFP-HOTag3-T2A-RILPL2-R130E-eGFP-HOTag6 or pcDNA3.1-Rab10-eGFP-HOTag3-T2A-RILPL2-R132E-eGFP-HOTag6 or pcDNA3.1-Rab10-eGFP-HOTag3-T2A-RILPL2-K149E-eGFP-HOTag6 plasmids were fully mixed into DNA dilution solution and allowed to stand for 5 minutes; 0.6 μL of PEI was diluted with 10 μL Opti-MEM serum-free medium. 40000 transfection reagent (YEASEN), mix thoroughly to make PEI40000 dilution solution, and let stand for 5 minutes.

[0076] b. Mix the DNA dilution and PEI 40000 dilution and incubate at room temperature for 20 minutes to form a DNA-PEI cationic nucleic acid transfection reagent complex.

[0077] c. After the complex formation process, remove 20 μL of cell growth medium and add 20 μL of DNA-PEI cationic nucleic acid transfection reagent complex to each well; shake the culture plate and mix gently.

[0078] d. The cells were cultured in a 37°C, 5% CO2 incubator. One hour after transfection, 75 μL of the original cell growth medium in the wells was removed and 175 μL of fresh pre-warmed DMEM high-glucose medium containing 10% FBS was added to each well to maintain the medium volume of each well at 200 μL.

[0079] (3) Photography: 24 hours after transfection, 12 fields of view were randomly selected from each well for photography using the CX7Pro high-content rapid imaging platform (Thermo Fisher) with a 20x high-definition lens. The experimental imaging results are shown in Figure 2. Figure 4 shown.

[0080] (4) Quantitative method: The position of the cell nucleus is determined by pCMV-Tag3B-3NLS-mCherry independently expressed in the probe, thereby determining the number of transfected cells; the total number of green phase change droplets in the field of view / total number of cells, that is, the average number of green droplets in each cell, is used to show the degree of LRRK2 kinase activation. The result data of the Rab 10 WT / RILPL2 WT group is taken as 1, and the graph is normalized. The specificity of the phase change probe of the present invention is verified by ① mutation of the threonine (Thr) phosphorylation site at position 73 of the LRRK2 kinase substrate Rab10 and ② mutation of the key amino acid residues (130, 132 or 149) for the specific binding of RILPL2 to pThr73-Rab10. The results are shown in the figure. Figure 5 The number of green fluorescent droplets in the Rab10 mutant and RILPL2 mutant groups was less than that in the Rab10 WT / RILPL2WT group, further demonstrating the specificity of the phase change probe of the present invention. Example 4

[0081] The specificity of the phase change probe of the present invention was verified by the mutation of LRRK2 kinase activity loss (KD); at the same time, the sensitive discrimination of the phase change probe of the present invention was demonstrated by detecting the changes in the kinase activity of the most common LRRK2-G2019S mutation in Parkinson's disease. The steps are as follows:

[0082] (1) Plating: HEK 293T cells were plated at 1.3 × 10 cells per well. 4 The cells were evenly plated on a 96-well cell culture plate at a density of 100 μL per well, and cultured in a 37°C, 5% CO2 incubator.

[0083] (2) Cell transfection: After the cells are plated and cultured for 20 hours, cell transfection is performed. The specific steps are as follows:

[0084] a. For each well of cells, use 10 μL Opti-MEM serum-free medium to dilute 100 ng pCMV-Tag3B-3NLS-mCherry, 250 ng / 150 ng / 50 ng pcDNA3.1-Rab10-eGFP-HOTag3-T2A-RILPL2-eGFP-HOTag6, and 12.5 ng blank vector or pCMV-Tag3B-LRRK2-WT or pCMV-Tag3B-LRRK2-G2019S or pCMV-Tag3B-LRRK2-3×KD plasmid, mix well to make DNA dilution solution, and let stand for 5 minutes; use 10 μL Opti-MEM serum-free medium to dilute 0.6 μL PEI 40000 transfection reagent (YEASEN), mix well to make PEI 40000 dilution solution, and let stand for 5 minutes.

[0085] b. Mix the DNA dilution and PEI 40000 dilution and incubate at room temperature for 20 minutes to form a DNA-PEI cationic nucleic acid transfection reagent complex.

[0086] c. After the complex formation process, remove 20 μL of cell growth medium and add 20 μL of DNA-PEI cationic nucleic acid transfection reagent complex to each well; shake the culture plate and mix gently.

[0087] d. The cells were cultured in a 37°C, 5% CO2 incubator. One hour after transfection, 75 μL of the original cell growth medium in the wells was removed and 175 μL of fresh pre-warmed DMEM high-glucose medium containing 10% FBS was added to each well to maintain the medium volume of each well at 200 μL.

[0088] (3) Photography: 24 hours after transfection, 12 fields of view were randomly selected from each well using the CX7Pro high-content rapid imaging platform (Thermo Fisher) with a 20x high-definition lens. The experimental imaging results are shown in Figure 2. Figure 6 shown.

[0089] (4) Quantitative method: The position of the cell nucleus is determined by the pCMV-Tag3B-3NLS-mCherry independently expressed in the probe, thereby determining the number of transfected cells; the total number of green phase-change droplets in the field of view / total number of cells, that is, the average number of green droplets in each cell, is used to show the degree of LRRK2 kinase activation. The analysis results of the comparison of kinase activity between LRRK2 wild type and LRRK2 gene mutant (LRRL2-G2019S) and LRRK2 kinase activity loss mutant (LRRL2-3×KD) are shown in the figure. Figure 7 Compared with the LRRK2-WT group, the number of green fluorescent droplets in the LRRL2-3×KD group was less, which once again demonstrated the specificity of the phase change probe of the present invention.

[0090] Among them, LRRK2-G2019S is a pathogenic mutation of Parkinson's disease, which is significantly different from LRRK2-WT. Therefore, this probe is also suitable for the detection of LRRK2 kinase activity in other different disease mutants. Example 5

[0091] The phase-change probe vector obtained in Example 1 was used to establish a high-content screening process for LRRK2 kinase inhibitors. The steps are as follows:

[0092] (1) Plating: HEK 293T cells were plated at 1.3 × 10 cells per well. 4 The cells were evenly plated on a 96-well cell culture plate at a density of 100 μL per well, and cultured in a 37°C, 5% CO2 incubator.

[0093] (2) After the cells were plated and cultured for 20 hours, cell transfection was performed. The specific steps are as follows:

[0094] a. For each well of cells, use 10 μL Opti-MEM serum-free medium to dilute 250 ng pcDNA3.1-Rab10-eGFP-HOTag3-T2A-RILPL2-eGFP-HOTag6 plasmid, 100 ng pCMV-Tag3B-3NLS-mCherry plasmid and 50 ng pCMV-Tag3B-LRRK2-G2019S plasmid, mix well to make DNA dilution solution, and let stand for 5 minutes; use 10 μL Opti-MEM serum-free medium to dilute 0.6 μL PEI 40000 transfection reagent (YEASEN), mix well to make PEI40000 dilution solution, and let stand for 5 minutes.

[0095] 2. Mix the DNA dilution and PEI 40000 dilution and incubate at room temperature for 20 minutes to form a DNA-PEI cationic nucleic acid transfection reagent complex.

[0096] 3. After the complex formation process, remove 20 μL of cell growth medium and add 20 μL of DNA-PEI cationic nucleic acid transfection reagent complex to each well. Shake the culture plate gently to mix.

[0097] 4. The cells were cultured in a 37°C, 5% CO2 incubator. One hour after transfection, 75 μL of the original cell growth medium in the wells was removed and 175 μL of fresh pre-warmed DMEM high-glucose medium containing 10% FBS was added to each well to maintain the medium volume of each well at 200 μL.

[0098] (3) Drug addition: After changing the medium, add three LRRK2 inhibitors: GNE-7915, PFE-360, and MLi-2 as positive control drugs to the positive cells transfected with pCMV-Tag3B-LRRK2-G2019S, pcDNA3.1-Rab10-eGFP-HOTag3-T2A-RILPL2-eGFP-HOTag6, and pCMV-Tag3B-3NLS-mCherry plasmids, respectively; add DMSO (dimethyl sulfoxide) as a negative control, and add the compounds to be screened. The final drug concentration in each well is 5 μM.

[0099] (4) Photography: 24 hours after transfection, 12 fields of view were randomly selected from each well for photography using the CX7Pro high-content rapid imaging platform (Thermo Fisher) with a 20x high-definition lens.

[0100] (5) Quantitative method: The position of the cell nucleus was determined by the independently expressed pCMV-Tag3B-3NLS-mCherry in the probe, thereby determining the number of transfected cells; the total number of green phase-change droplets in the field of view / total number of cells, that is, the average number of green droplets in each cell, was used to show the degree of LRRK2 kinase activation. The result data of the negative control group with DMSO added was taken as 1 and normalized for plotting. The experimental analysis results are shown in Figure 2. Figure 8 shown.

[0101] (6) Statistical method: Use high-content software (General Spot Measurement Tool module of Thermo Scientific HCS Studio: Cellomics ScanVersion 6.6.3) to count the total number of green phase change droplets and the total number of cells in each sample well. The total number of green droplets in each sample well is divided by the total number of cells, and the average value is calculated to show the degree of inhibition of LRRK2 kinase by the screened compounds. The result data of the negative control group with DMSO added is taken as 1 and normalized for plotting. The lower the ratio, the more obvious the inhibitory effect of the compound on LRRK2 kinase. Screening is performed using 0.5 as the standard, and compounds with results less than 0.5 are compounds that have an inhibitory effect on LRRK2 kinase. Furthermore, compounds with results less than three LRRK2 inhibitors are compounds that have an inhibitory effect on LRRK2 kinase better than the three LRRK2 inhibitors, such as Figure 8 As indicated by the arrow, in pcDNA3.1-Rab10-eGFP-HOTag3-T2A-RILPL2-eGFP-HOTag6, the molar ratio of Rab10 to RILPL2 protein expression is 1:1, which achieves accurate quantification of high-content imaging and is suitable for high-content screening.

[0102] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A phase change probe of LRRK2 kinase, characterized in that: The phase change probe includes DNA sequences encoding the following proteins or peptides in sequence: Rab10-Linker1-eGFP-Linker2-HOTag3-T2A-RILPL2-Linker1-eGFP-Linker2-HOTag6; Wherein, the DNA sequence encoding Rab10 is shown as SEQ ID NO.1; Wherein, the DNA sequence encoding Linker1 is shown as SEQ ID NO.2; Wherein, the DNA sequence encoding Linker2 is shown as SEQ ID NO.4; Wherein, the DNA sequence encoding HOTAg3 is shown as SEQ ID NO.5; Wherein, the DNA sequence encoding RILPL2 is shown as SEQ ID NO.7; Among them, the DNA sequence encoding HOTAg6 is shown as SEQ ID NO.

8.

2. The phase change probe according to claim 1, characterized in that: The DNA sequence encoding eGFP is shown in SEQ ID NO.

3.

3. The phase change probe according to claim 1, characterized in that: The DNA sequence encoding T2A is shown in SEQ ID NO.

6.

4. A use of the phase change probe according to any one of claims 1 to 3 for non-disease diagnosis purposes in detecting LRRK2 kinase activity.

5. Use of the phase change probe according to any one of claims 1 to 3 in screening LRRK2 kinase inhibitors.